DEFA14A: Walgreens Boots Alliance to Be Acquired by Sycamore Partners in $23.7 Billion Deal

Walgreens Boots Alliance (WBA) has entered into a definitive agreement to be acquired by Sycamore Partners for a total consideration of up to $23.7 billion, including cash and future proceeds from the monetization of VillageMD businesses.

Summary

• Walgreens Boots Alliance (WBA) has agreed to be acquired by Sycamore Partners.
• The total transaction value is up to $23.7 billion.
• WBA shareholders will receive $11.45 per share in cash at closing.
• Shareholders will also receive a non-transferable right (DAP Right) to receive up to an additional $3.00 per share from the future monetization of WBA's debt and equity interests in VillageMD.
• The cash consideration represents a 29% premium to WBA's closing share price on December 9, 2024.
• The total consideration represents a premium of up to 63% to the same share price.
• The transaction is expected to close in the fourth quarter of calendar year 2025.
• Sycamore has secured fully committed financing for the transaction.
• Stefano Pessina and his holding company, owning approximately 17% of WBA's shares, will vote in favor of the transaction and reinvest their cash consideration into the acquiring company.
• VillageMD debt to WBA is $3.4 billion as of February 28, 2025, with PIK interest of 19% per year.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the premium offered to shareholders and the potential for future value creation. However, risks associated with regulatory approvals, financing, and the monetization of VillageMD businesses temper the overall outlook.

Positives

• Shareholders receive a premium cash value of $11.45 per share.
• Shareholders have the potential to benefit from additional value creation from the monetization of the VillageMD businesses through DAP Rights, potentially adding up to $3.00 per share.
• Sycamore Partners' expertise in retail and consumer services is expected to enhance WBA's turnaround strategy.
• The transaction is not subject to a financing condition, increasing the likelihood of completion.
• Stefano Pessina's reinvestment demonstrates confidence in the future of the business.

Negatives

• The additional $3.00 per share is contingent on the successful monetization of the Divested Assets and is not guaranteed.
• The transaction requires shareholder and regulatory approvals, which could delay or prevent the deal from closing.
• The company will be delisted from the Nasdaq Stock Market and become a private company.
• There is a risk that the holders of Divested Asset Proceed Rights will receive less-than-anticipated payments or no payments with respect to the Divested Asset Proceed Rights after the closing of the proposed transaction and that such rights will expire valueless.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Sycamore Partners may fail to obtain the necessary financing arrangements.
• The transaction may not receive the required regulatory and shareholder approvals.
• An event, change, or circumstance could lead to the termination of the transaction agreements.
• The announcement or pendency of the transaction could negatively impact WBA's business relationships and operations.
• WBA may face challenges in retaining key personnel and maintaining relationships with business partners.
• Potential litigation related to the proposed transaction could arise.
• Restrictions during the pendency of the transaction may impact WBA's ability to pursue business opportunities.
• There is uncertainty regarding the timing of the completion of the proposed transaction.
• The holders of Divested Asset Proceed Rights may receive less-than-anticipated payments or no payments.

Future Outlook

The company expects to close the transaction in the fourth quarter of calendar year 2025, subject to customary closing conditions, including shareholder and regulatory approvals. WBA aims to become the first choice for pharmacy, retail, and health services.

Management Comments

• Tim Wentworth, Chief Executive Officer, stated that the transaction provides shareholders premium cash value with the ability to benefit from additional value creation from monetization of the VillageMD businesses.
• Stefan Kaluzny, Managing Director of Sycamore Partners, expressed confidence in WBA's pharmacy-led model and its essential role in driving better outcomes for patients, customers, and communities.

Industry Context

Private equity firms are increasingly targeting established retail and healthcare companies for turnaround opportunities. Sycamore Partners' acquisition of WBA aligns with this trend, leveraging their expertise in retail and consumer services to improve WBA's performance in a rapidly evolving pharmacy industry.

Comparison to Industry Standards

• Comparable transactions in the retail pharmacy space include CVS's acquisition of Aetna and Rite Aid's various asset sales.
• The premium offered to WBA shareholders is within the typical range for similar acquisitions, but the structure involving DAP Rights adds complexity and uncertainty.
• Sycamore Partners' track record in retail turnarounds will be crucial in assessing the potential success of this acquisition.

Related Party Transactions

• Stefano Pessina, WBAs Executive Chairman, and his holding company will vote in favor of the transaction and reinvest their cash consideration into the acquiring company.

Stakeholder Impact

• Shareholders will receive a premium for their shares and have the potential for additional value through DAP Rights.
• The company aims to positively impact the health outcomes and overall well-being of its customers, patients, communities, and team members.
• WBA will maintain its headquarters in the Chicago area and continue contributing to the communities in which it operates.
• The company's trusted brands and deep commitment to its stakeholders will continue to anchor its business.

Next Steps

• WBA will file a definitive proxy statement on Schedule 14A with the SEC.
• The company will hold a special meeting of stockholders to vote on the proposed transaction.
• The Divested Assets Committee will determine the nature and timing of the process to maximize value of WBAs debt and equity interests in the Divested Assets.
• The company will seek required regulatory approvals.
• The transaction is expected to close in the fourth quarter of calendar year 2025.

Key Dates

Keywords

Walgreens Boots Alliance, Sycamore Partners, acquisition, merger, VillageMD, DAP Rights, shareholders, monetization, private equity, retail, healthcare